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MediAdvanced Age as a
Primary Determinant of
Cardiovascular Disease
Recent decades have witnessed striking growth in
the number of older adults both in the United
States and throughout much of the world, largely
due to improved public health, nutrition, and med-
ical care. Between 2000 and 2030, the proportion of
the world’s population age 65 years and older is
expected to increase from 6.9% to 12% (1). In the
nited States, the “old age” demographic is accel-
rating even more rapidly (estimated to increase
rom 12.9% to 20% between 2000 and 2030) as
aby boomers enter their senior years (2). Further-
more, by 2050, the subgroup of U.S. seniors age 85
years and older is expected to triple. Ironically,
aging also catalyzes fundamental changes that in-
rease susceptibility to cardiovascular disease (CVD)
uch that CVD is endemic in the burgeoning senior
opulation (3). Already, the prototypical U.S. car-
iology patient is an older adult, and management
f cardiac issues is fundamentally linked to the
railties and multimorbidities associated with ad-
anced age.
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Although many assume that cardiologists are logical
healthcare leaders for management of CVD in seniors,
the current cardiovascular (CV) armamentarium fails to
integrate complexities or needs specific to older patients.
Conventional evidence-based standards of CV care were
formulated using trial data derived from younger study
populations and/or elderly patients who were rigorously
screened to exclude common morbidities or frailties of
old age (4). As a result, routine CV management often
overlooks health problems without a cardiac focus (e.g.,
cognitive decline, functional limitations, pain, or multi-
morbidities) even if they bear on how patients experience
and process CV healthcare decisions (5). Primary care
providers may even choose to avoid cardiology consul-
tation if they perceive that the cardiologist will recom-
mend medications and procedures that are discordant
with the patient’s overall care priorities (6). Moreover, in
ome areas of the United States, third-party payers are
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hat are perceived to be invasive procedures that add
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use of stents in stable coronary artery disease patients, an issue
particularly germane to older adults, given the high age-related
prevalence of coronary artery disease.
It is indisputable that the attributable risk of CVD is
highest in the senior population (8–10). Therefore, CV
caregivers have the greatest potential to favorably impact
mortality and morbidity by implementing preventive and
interventional therapies in their oldest patients. Yet, this
potential is counterbalanced by increased iatrogenic risks as
well as myriad medical, social, and even economic concerns
that can affect which issues a patient considers his/her
paramount concerns. To navigate through these cross-
currents, cardiologists require additional proficiencies, that
is, insights and skills that require deliberate preparation and
training.
The Institute of Medicine’s recent report on retooling for
an aging America emphasizes the need for fundamental
reform in healthcare training and implementation to meet
the needs of the older population (11). “The nation needs to
move quickly and efficiently,” the report indicates, “to make
certain that the healthcare workforce increases in size and
has the proper education and training to handle the needs of
a new generation of older Americans.”
We propose that fundamental tenets of CV training
and patient management can and should be expanded to
better address the complexities of all patients, including
skills and insights to better treat the large and growing
population of older adults who now comprise the largest
subgroup of CV patients. Training should continue to
emphasize state-of-the-art technological and medical
expertise, but also their individual application, and
should ensure that all providers have the skills needed to
assess patient preferences, circumvent hazards of hospi-
talization, facilitate successful transitions from one care
setting to the other, engage in useful risk-benefit discus-
sions, and provide care collaboratively within a care team
responsive to the needs of the oldest patients. Such
enhancements will lead to more individualized care, with
better coordination across multiple conditions.
Aging Leads to Changes in the
Nature of CVD and its Management
Although chronology is relevant, the process of aging entails
more than an accounting of years lived (12). Relative
differences in biology (e.g., telomere length, oxidative stress,
inflammation, genetic constitution) (13–15), lifelong health
habits (e.g., nutrition, exercise, dental care), cardiac risk
factors (e.g., hypertension, cholesterol, tobacco, insulin
resistance) (16), comorbidities (e.g., infection, chronic ob-
structive pulmonary disease, renal disease, anemia, arthritis,depression, dementia, vision and hearing deficits), psychol-
ogy (e.g., interpersonal capacities, self-efficacy, coping skills),
social structure (e.g., class, community, access, spouse,
family support), economic resources (personal, governmen-
tal), and culture (religion, ethnicity, transcendent sense of
meaning and purpose) also impact the aging process. There-
fore, a more meaningful way to conceptualize “aging” is as a
continuum of changes that mount over time, with pace and
nature of progression varying depending on each person’s
circumstances.
Despite such individual variation, 75 years is often
cited as the beginning of old age, in part because it
provides a convenient benchmark for research and clinical
applications. Likewise, 85 years is often used as a
convenient threshold to classify very old age. These
designations presume that by 75 and 85 years, respec-
tively, most adults have sustained sufficient aging changes
to exhibit clinically relevant differences in physiology and
organ function and reserves. Yet, aging remains idiosyn-
cratic, and each senior adult has a unique constellation of
age-related vulnerabilities and consequences.
High age-related incidence of CVD arises in part due to
broader aging processes, including accumulating morbidi-
ties, diminishing homeostasis, and prolonged injurious ef-
fects of CV risk factors (3,17). Cardiac disease also stems
from insidious age-related changes in CV morphology and
function. Vascular stiffening of the central vasculature is, for
example, an omnipresent aging phenomenon that usually
starts by middle age and leads to progressive rise of afterload
stress, myocardial workload, and changes in diastolic perfu-
sion that predispose to functional decrements and ultimately
to ischemia, heart failure, arrhythmia, and other CV disor-
ders (18–20). Heart failure with preserved ejection becomes
increasingly common as the mounting aortic impedance of
senescence is more likely to uncouple from ventricular
pumping performance (21). Parallel aging changes in myo-
cytes, endothelial cells, and pacemaker cells further increase
vulnerability to coronary artery disease, valve disease, heart
failure, arrhythmia, peripheral artery disease, and cerebro-
vascular disease (20). The relative progression of each of
these aging effects varies among individuals, resulting in a
diverse range of CV clinical implications. For some seniors,
CV aging is manifest only as functional decrements (22),
whereas others develop subclinical (23) or overt CVD
(3,17,20,24). Although, overall, CVD increases appreciably
with age, cardiologists face the challenge of tailoring pre-
vention and treatment priorities relative to each individual’s
circumstances.
CVD is also usually more hazardous in older patients. It
often erupts with multiple simultaneous CVD processes
(e.g., acute coronary syndrome, heart failure, and atrial
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(e.g., pneumonia, renal insufficiency, anemia, chronic lung
disease, diabetes, and stroke) (24). Such multisystem disease
combinations are more liable to overwhelm the diminished
CV reserve capacity of aging, thus leading to adverse
outcomes. Medications often compound problems, as age-
related changes in absorption and metabolism alter the
pharmacokinetics and pharmacodynamics of most drugs. As
a result, medication dosing and effects, both beneficial and
adverse, often differ from those in younger adults, and it
cannot be assumed that the clinical utility of agents shown
to be effective in younger individuals necessarily applies to
the elderly. Moreover, especially given the likelihood of
multiple cardiac and noncardiac diseases occurring simulta-
neously among older CVD patients, clinically significant
drug–drug and drug–disease interactions are ubiquitous,
adding to management challenges (25).
Limitations of the
Current Therapeutic Paradigm
Despite the glaring pattern of age-related complexity and
the precarious onset and progression of disease, the current
paradigm of care for older CV patients is relatively rudi-
mentary, mostly an extrapolation from conventional
evidence-based CV guidelines. Even the recently revised
non–ST-segment elevation myocardial infarction guide-
lines, which called for special considerations in care of older
populations, provided little in the way of concrete recom-
mendations (26). Essentially, cardiologists have begun to
approach the margins of the issue, but have yet to deal with
it programmatically.
Evidence-based care becomes considerably less certain
when analyzed through a lens that exposes relevant aging
dynamics. For example, although an impressive array of trial
data suggests utility of statins to reduce mortality for older
adults (27,28), therapeutic ambiguity persists if the statin
constitutes the eighth pill in a complex regimen and/or if
the patient has age-related renal insufficiency and/or nebu-
lous muscle aches (29,30). Not only are the salutary effects
of a multipill regimen for a frail elder unclear, but dimin-
ished access to care, costs, iatrogenesis in relation to age,
polypharmacology, and morbidity remain substantial con-
cerns, with absent clarification from the clinical trials on
which treatment indications were based, that is, trials that
systematically excluded older patients with such complexi-
ties (4). Furthermore, data pertaining to adults age 80 years
and older remain generally absent, and benchmark mortality
endpoints are often of less concern for seniors than quality-
of-life issues (e.g., myalgias, polypharmacology, and medi-
cation costs).Part of the challenge is that many CV interventions
effective in younger patients are more likely to adversely
affect older adults, especially those weakened or debilitated
by age (31). Contemporary proliferation of drug-eluting
stents and antiplatelet therapy, for example, is counterbal-
anced by increased bleeding risks in older patients (32).
Beta-blockers can limit chronotropy and exercise perfor-
mance. Nitrates can increase falls and syncope. Idiosyncratic
effects of age must be anticipated. Complexities are exacer-
bated by cognitive decline, confusion, mood changes, and
loss of appetite, especially in a context of common stresses of
hospitalizations, loss of independence, functional declines,
polypharmacology, and sensory impairments (vision, hear-
ing, taste). Precise dosing of medications and monitoring
are essential, as is thorough assessment of composite life
events that impact on CV health and care.
Advanced age and frailty also often confound conven-
tional processes of care. Access to caregivers is often more
limited (hindering assessments and monitoring); vision,
hearing, and cognitive limitations can complicate compre-
hension and compliance; arthritis impedes exercise goals;
financial constraints and altered taste may frustrate dietary
recommendations; finances may also prohibit use of vital
ancillary services; even the ability to stand on a scale can
become difficult for someone challenged by dizziness,
stroke, or Parkinsonism. Therapy that merely extrapolates
from standards oriented to younger populations might be
fundamentally unsuitable for someone old and frail.
Not only do higher risk–benefit ratios exist among
seniors for virtually all CV procedures and interventions
relative to the populations from which evidence-based
standards were derived, but even if/when study endpoints
are reproduced in seniors, many patients may not perceive
them as benefits.
The manner and quality of death can also be affected by
therapeutic choices in ways far removed from their original
therapeutic intent. An implanted cardioverter-defibrillator
may, for example, prevent sudden (painless) death, but this
“benefit” inevitably increases the likelihood of dying from
congestive heart failure, myocardial infarction, cancer, or
other noncardiac causes (33,34). Such consequences are
often not anticipated and discussed prior to undertaking
therapeutic interventions.
Limitations of the current CV healthcare paradigm to
care for seniors extend beyond decisions made for an
individual patient and relate to the healthcare industry. Over
the last decade, access to CV imaging, procedures, and
devices have expanded for older adults. There has, for
example, been enormous investment in nuclear imaging on
the premise of quality (35), often usurping the role of
traditional electrocardiogram exercise testing that still might
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clinical questions (e.g., prognosis, exercise capacity, and
symptoms) without the added expense of imaging (36).
These issues are now compounded by the growth of
computed tomography and other imaging options that tout
clinical benefits, but for which outcomes data are lacking.
Although concerns regarding over-reliance on imaging are
not exclusive to older patients, prevalence of CVD increases
with age (such that application of imaging assessments also
escalates) as does a common (but erroneous) assumption
that older patients cannot exercise sufficiently for clinically
useful nonimaging assessments.
Improving Care of
the Older Cardiac Patient
A New Clinical Paradigm
Given the fundamental heterogeneity of aging and its direct
bearing on clinical management, improved care for older
CV patients is a priority (37). Considerable work lies ahead
to achieve what are still sometimes idealized goals that must
be better delineated and then promoted amid many con-
Table 1
New Paradigm of Care
1. Emphasize patient-centered approach to care
 Develop tools to assess cardiovascular risk in the context of aggregate age-re
Œ Develop tools to determine realistic goals in the context of each patient’s o
 Incorporate noncardiac comorbidity, functional capacity, and quality-of-life
Œ Incorporate patient preferences into care plan
 Assessment of end-of-life preferences, including development of advance
and (if appropriate) discussion of palliative care options
 Assess utility of diagnostic testing relative to overall treatment goals
2. Screen for coexisting geriatric syndromes and comorbidity (e.g., cognitive functi
 Incorporate standardized geriatric tools (e.g., gait speed, “get up and go” test
 Screen for depression and/or anxiety
 Screen for caregiver stress, home support
3. Purposefully manage pharmacological regimen
 Adapt dosing regimen and targets of therapy emphasizing tolerability and affo
Œ Use weight- and renal-adjusted dosing (if appropriate)
Œ Focus on potential drug–drug and drug–disease interactions
Œ Assess relative risk and benefit of additional medications
Œ Utilize services of a geriatric pharmacist (if available)
 Increase vigilance for drug side effects/intolerance
Œ Enlist assistance of care providers
Œ Reconcile medication during all care encounters (particularly following care
 Simplify medication regimen if possible (“unprescribe”)
✓ Ensure provision of tools (e.g., pillboxes, written instructions)
4. Emphasize the importance of transitions of care
 Improve methods of communications among caregivers and with patients; pla
care delivery
Œ Use nurse clinicians or pharmacists to provide added support
Œ Provide clear contact information for all patients when questions arise.
Œ Ensure transparency in care across providers through more effective utilizat
Œ Create a central repository listing all medications, doses, and frequencies
 Provide patient education designed to promote self-care behaviors and foster
and other health-promoting behaviors
 Make greater utilization of rehabilitation services, including facility- and home-
including home monitoringtrasting and competing versions of healthcare priorities
(Table 1).
Improved CV management for seniors must start with
the capacity for comprehensive assessment of each individ-
ual’s health as well as a multifaceted health context, with
therapy then personalized to each patient’s situation. Tools
to gauge overall health and to link composite health profiles
to customized and achievable therapeutic goals are needed.
Patients must be engaged in the selection of the manage-
ment choices bearing on their health, but the medical
system (and cardiologists in particular) must achieve pro-
cesses, organization, and standards that insure that seniors
receive lucid, relevant information in a straightforward
comprehensible manner.
Although longevity may remain the dominant priority for
some older adults, the prospect of excessive pain, hardship
(including perceived burden on loved ones), limitation of
independence, and/or recurrent hospitalizations may limit
appeal of life-prolonging therapies, particularly amidst chronic
disease and progressive debilitation. Just as cardiology has
cultivated vast insight and expertise oriented to extending
longevity, it now is crucial to refine health goals oriented to a
risk
health circumstances
s into risk-benefit assessment of care options
ives, designation of durable power of attorney for health care,
ability, and frailty in patients 75 years of age)
-Mental State Examination, and so on)
y
ions)
ollaborative follow-up and assessment to prevent gaps or overlaps in
electronic medical records and traditional methods of correspondence
nce to medications, diet, activity recommendations,
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tional capacity, reduced hospitalizations, and independence.
The evidence-based foundation of CV medicine must expand
to achieve insights and rationales that support and guide these
nonmortality objectives.
Although in some cases, clarification of therapeutic ob-
jectives may be as simple as direct patient inquiry, this
process will often be confounded by affect, cognitive decline,
social pressures, and/or family dynamics, especially in situ-
ations involving advance directives or healthcare proxies.
Furthermore, given that aging is dynamic, therapeutic goals
may fluctuate relative to advancing age and circumstances.
Interviewing techniques and assessment strategies must be
efficient, sensitive, and reliable for recurrent assessments for
a wide range of personalities and settings.
Risk stratification is a related dimension of assessment
that is particularly important in assessing eligibility of older
adults for CV procedures (38–40). The goal is not to
restrict treatment, but to better select patients for therapy
who are most likely to benefit. The decision to undertake
revascularization should be based, not solely on results of
imaging procedures and anatomical criteria, but on aggre-
gate patient circumstances. Coronary anatomy is relevant,
but so too are comorbid features (e.g., renal, pulmonary)
that impact procedural success and complications. Likewise,
even technically successful revascularizations may culminate
suboptimally if cognitive, comorbid, and social limitations
were not recognized and addressed prior to undertaking the
procedure. Beyond conventional parameters of coronary
anatomy and comorbidities, seminal work by Fried et al.
(41) highlights that many aspects of frailty also impact CV
outcomes; for example, unintentional weight loss, weakness,
self-reported exhaustion, slowness of gait speed, low activ-
ity, and poor grip strength are important considerations.
Assessments once seen as “soft” or subjective (e.g., fatigue,
weakness, gait speed) are now increasingly acknowledged as
providing important prognostic information. Such innova-
tive assessments have been reinforced by tools to increase
their reliably and objectivity (42–45), which are important
refinements to refute those who still see them as soft and
inconsequential. Cognition (delirium risk) (46), social sup-
port, and mood (depression) (47) must be considered in
assessing risk. Concomitant pharmacotherapy should also
be taken into consideration; for example, chronic need for
warfarin increases bleeding risk following percutaneous
coronary intervention, and may affect the choice of anti-
platelet therapy or the type of stent to deploy (i.e., bare-
metal vs. drug-eluting stent) (48).
For patients prioritizing quality of life, function, inde-
pendence, and other clinical goals over longevity benefits,
therapeutic strategies must shift. Although digoxin did notreduce mortality in the DIG (Digitalis Investigation Group)
trial, more important may be its benefit in reducing heart
failure symptoms and related hospitalizations in older pa-
tients (49). Although milrinone for systolic HF may be
associated with increased mortality risk, its potential to
increase function and quality of life may seem worth that
risk to an elderly patient (50). Even therapeutic bastions like
beta-blockers may seem less useful for frail heart failure
patients whose vulnerability to chronotropic incompetence
(and potential need for a pacemaker with associated proce-
dural risks and other adverse outcomes) and functional
decrement may outweigh their life-prolonging benefits.
Similarly, rationale for stents, devices, and surgery must
be reconsidered in terms of their value with respect to the
personalized clinical goals of each patient. Whereas the
utility of revascularization to increase life expectancy may
seem nebulous, its value may seem relatively clear cut if
improved function, quality of life, and independence are the
primary therapeutic objectives (51). Treatment pathways
can be delineated in ways that help patients, families, and
allied caregivers understand which older patients are most
likely to benefit. Likewise, procedures can be refined and
standardized to better facilitate these goals (e.g., type of
stent, hybrid procedures, and/or adjunctive therapy). The
onus is on cardiologists to achieve technological and meth-
odological advances to best assure excellent outcomes for
seniors, and to disseminate these refinements as priorities.
Bivalirudin and fondaparinux may, for example, be better
antithrombin agents for older adults undergoing percutane-
ous coronary intervention (52–54). Sheath sizes, antiplatelet
therapy, and other clinical processes may be better tailored
to specific patient criteria. Similar approaches to minimize
age-related renal toxicity, delirium, and other morbidity are
all mandated.
Fundamental strategies of therapy may also change to
better manage the risks and limitations associated with age,
and to achieve outcomes that are particularly valued. The
recent report of success with transcutaneous aortic valve
implantation (TAVI) in patients ineligible for traditional
valve surgery provides an excellent example of how techno-
logical advances may better facilitate successful patient-
oriented outcomes (e.g., improved independence and qual-
ity of life) for patients who would be unlikely to benefit from
traditional therapeutic strategies (55).
Improving Communications and
Transitions for Older CVD Patients
Improved communications are vital to all dimensions of
care. Many older adults have natural barriers to optimal
communication due in part to diminished cognitive and
memory capacities, auditory and visual impairments, and
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medical issues (i.e., it is simply hard for many to understand
the concepts). Communications are critical for patients to
grasp complex concepts of aggregate health risk and be able
to make personalized healthcare choices. Given these typical
obstacles, language and learning tools can be refined and
standardized to be more effective. Not only can doctors,
nurses, and other staff be better trained to communicate
with older patients by adapting to individual patient’s health
literacy, education level, cognitive function, and culture, but
hearing, vision, and learning props can be integrated at key
junctures of care. Well-coordinated information can also be
provided to families, spouses, and others involved with a
patient’s care, being careful not to undermine the patient’s
autonomy and right to make choices, but rather to insure
consistency, clarity, and a shared sense of information.
Equally important, information should be readily available
to all caregivers involved in each patient’s care (i.e., primary
care physicians, hospitalists, other specialists, nurses, phys-
ical therapists, and nutritionists) with the goals of consis-
tency in information exchange and minimizing iatrogenesis.
A related priority is that cardiologists communicate effec-
tively with their medical colleagues. Optimal CV care
demands a team approach to address the complexities of
older patients. CV management must be coordinated within
the caregiving team; unambiguous and timely information
flow and documentation are essential (56).
Communications also relate to the ability of CV special-
ists to hear senior patients (i.e., not only as part of the
process to determine personalized therapeutic goals, but as a
means to gauge the efficacy of therapy). Especially given
that many nonmortality endpoints rely on qualitative pa-
rameters, listening and hearing are elemental components to
assess caregiving quality and effectiveness (57).
Cardiac rehabilitation can be better utilized to reduce
morbidity and mortality, improve quality of life, increase
functional capacity, reduce readmissions, and reduce health-
care costs for elderly patients (58). Cardiac rehabilitation
specifically responds to challenges experienced by most
older CVD patients, that is, multimorbidities and complex
medication regimens. Unfortunately, access remains a sub-
stantial impediment, and there has been little in the current
healthcare financial environment to ease this problem.
Although many older patients are not referred because they
are deemed too frail, these patients often achieve the
greatest benefit.
Improved transitions of care have also been demonstrated
to confer significant value for seniors (59–61). Certainly,
cardiac rehabilitation can help in the transition of cardiac
patients to home, but transitions also pertain to those
entering the hospital, transferring between hospital units, orreturning to home after rehabilitation. Transitions are often
particularly detrimental among those with multimorbidities
and frailty, especially those with cognitive and sensory
(vision/hearing) limitations. Steps that reinforce communi-
cations, consistency in medications, diminished confusion
and agitation, and timely follow-up will best ensure success-
ful outcomes, as well as help relieve stress, improve quality
of life, and increase long-term adherence.
Financial Emancipation From
the Current Paradigm of Health Care
Although a comprehensive discussion of the implications of
aging on healthcare finances is beyond the scope of this
manuscript, reimbursement for healthcare services must
become better aligned with, and more mindful of, age-
related dynamics. Current reimbursement strategies provide
incentive for performance of high-tech diagnostic and
therapeutic procedures and disincentive for physicians to
spend extra time discussing management options and pa-
tient preferences with older patients Furthermore, low-tech
therapies, such as patient education, smoking cessation, and
cardiac rehabilitation are poorly compensated or not com-
pensated at all, despite their proven benefit in reducing
CVD risk and/or improving outcomes. The fact that cardiac
rehabilitation enrollment falls to 12% of eligible elderly
CVD patients is a glaring example (58,62) of an underuti-
lized low-tech therapy that has been clearly associated with
both life-enhancing and life-prolonging benefits. Although
an abundant literature speaks to typical barriers, including
limited physical access (many cannot drive), spousal respon-
sibilities (particularly women who cannot participate due to
caregiving obligations for their husbands), and finances
(even the co-pay is prohibitive to many) (59), there has been
little effort to overcome these obstacles as an integral
component of healthcare reform legislation. Other low-tech
options that merit greater application include community
and home-care exercise programs, transportation services,
spousal care services, and homecare providers (to help older
patients organize medications, shopping and cooking, and
physician appointments and bills). Although additional
study is needed, all of these services would likely be greatly
valued by many elderly CVD patients, thereby improving
quality of life. There is also significant potential for these
services to improve clinical outcomes, including hospitaliza-
tion rates, and lower overall costs of care.
Including Family in the Spectrum of Care
In general, goals to improve CV care for seniors pertain not
only to the older patient, but to the family caregivers whose
lives are commonly consumed with and/or mired in the
patient’s health issues. Cardiology has rarely addressed the
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medication regimens, CV-related functional impairments
and dependencies, procedures, and other aspects of CV care,
despite awareness that associated morbidity and mortality
risks for caregivers are significant (63). Steps to personalize
therapeutic goals, enhance communications, and improve
transitions will benefit not only patients, but family care-
givers as well.
End-of-Life Planning in the Spectrum of Care
End-of-life issues should also be better incorporated into
routine management. Open discussion about mortality can
help ease feelings of isolation, depression, and even self-
blame for treatment failure among patients nearing the end
of life (64). Accepting the inevitability of death as part of
the normal human life trajectory, rather than as an enemy to
be avoided at all times, can help refocus management
choices away from options that may no longer be useful or
relevant. A recent study highlights that implantable
cardioverter-defibrillators are rarely deactivated for hospice
patients, with many futile and painful shocks in the last
months of life (55). Thresholds for therapeutic curtailment
for devices as well as medications should be established a
priori and implemented when appropriate, without drama,
guilt, or delay. Often this requires that physicians and allied
caregivers teach patients and families about reasonable
expectations. This requires insight, nuance, language, and
end-of-life sophistication to help patients make well-
informed decisions.
Personalized approaches to care may also help contain
costs. Many have decried disproportionate soaring CV
healthcare expenditures during the last weeks of life (65,66).
More widespread use and implementation of advance direc-
tives, including honoring patients’ expressed wishes, will
facilitate appropriate curtailment of aggressive care, includ-
ing hospitalization, in patients approaching the end of life.
Additionally, alternative approaches to care, such as home
hospital and hospice, should become increasingly accepted
by the medical community and supported by payers as being
valid and cost-effective methods for providing medical care
in appropriately selected patients.
Integrating Geriatrics Into CV Care
Although cardiologists have a long tradition of providing
outstanding care for CV disorders, cardiology has not
prioritized tools and techniques to manage CVD as part of
a multisystem approach to care. Cardiologists could learn
from geriatricians, that is, clinicians specifically trained to
assess different systems in juxtaposition to one another, and
to design management plans that extend across different
dimensions of health. Geriatricians also have better tools tomodify care relative to cumulative aging changes, mounting
disabilities, and to consider quality of death as part of
standard care. In other words, geriatricians provide a useful
language and process that can be used to augment quality
and capacity of cardiac specialists to meet the needs of their
older patients (67).
The American College of Cardiology recently launched a
new Council on Cardiovascular Care for Older Adults.
Almost simultaneously, the American Heart Association
established a new committee on Cardiovascular Disease in
Older Populations. These steps reflect awareness of the
need to address the aging issue programmatically. Both
groups are in their infancy, but provide opportunity to
advance the issues addressed in this document and to
facilitate integration of geriatric cardiology into mainstream
CV care.
Research and Education
Research is essential to determine optimal strategies to care
for older patients with CVD. It is critical that clinical
datasets include comorbidity, polypharmacy, and frailty in
order to better define the impact of these factors on
prognosis and response to therapy. Outcomes must also be
broad, and inclusive of function, quality of life, and iatro-
genesis, since these dynamics are integral to the assessment
of therapeutic efficacy.
Today’s expanding arena of clinical datasets at the Amer-
ican College of Cardiology and throughout the world
provide abundant opportunity to assess the efficacy of
diagnosis and risk stratification, to assess the impact of
specific treatments on relevant clinical outcomes (e.g., qual-
ity of life and health status), and to help refine overall
clinical decision making to optimize older patients’ care and
outcomes. However, inclusion of functional and health
status indexes into large registries and trial databases often
remains encumbered by concerns regarding additional costs
(who should pay for exercise assessments?), lack of stan-
dardization (how can qualitative measures be as objective as
a mortality endpoint?), and high variance (particularly in
regard to functional measures such as a 6-min walk). Yet, in
the face of the prominent upsurge in the geriatric demo-
graphic, these methodological challenges must be resolved
(68,69); steps to integrate functional (70) and qualitative
measures as standards are essential research goals.
Research can also address the complex relationship be-
tween aging and disease such that CVD in the elderly may
be prevented by constitutive steps that modulate mecha-
nisms of aging that predispose to disease. It is fascinating,
for example, that caloric restriction may better allay age-
related alterations in left ventricular diastolic filling param-
eters than pharmacological modalities (71). Modification of
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striction or other novel therapies outside the current thera-
peutic paradigm may prove to be more effective than
conventional medications for moderating morbidity in older
CV patients (72).
The aging theme can also be trivialized by studies that do
not focus on the real complexities of age. Whereas many
studies claim merit simply on the basis of studying subsets of
older patients, the challenge is to determine if and how less
highly-selected seniors may be distinct and whether there
are fundamentally better healthcare choices and processes
for senior patients. Research must facilitate the tools, skills,
systems, and capacities needed to better deal with the
complex older adults who are our real patients.
It is conspicuous that several major CV syndromes that
are relatively exclusive to older adults (e.g., isolated systolic
hypertension, heart failure with preserved ejection fraction,
calcific/degenerative aortic stenosis) (73,74) remain poorly
understood and/or treated. Improved understanding of the
biology of these disorders should lead to opportunities for
new therapies, both pharmacological and biological (75), as
well as a greater appreciation for the benefits of lifestyle
modifications (76). In a related theme, many CV issues that
increase in prevalence with aging often become categorized
as primarily CV issues, such that pertinent geriatric dimen-
sions are overlooked. For example, although atrial fibrilla-
tion increases markedly with age, it is usually managed as a
complex CV issue, typically emphasizing electrophysiolog-
ical, cardiac, hemodynamic, and vascular parameters. In
contrast, age-centric dimensions of atrial fibrillation care,
such as polypharmacology, functional capacity, and bleeding
risks, are less routinely stressed.
In view of the crucial need for clinical and basic research
on CV disease in the older population to address its rapidly
escalating impact, it is increasingly important to forge
collaborative relationships amongst the key federal insti-
tutes, such as the National Institutes of Health, the Food
and Drug Administration, Center for Medicare Services,
Agency for Healthcare Research and Quality, and others, as
well as nonprofit organizations to spawn research that will
better inform clinical decision making, policy, and reim-
bursement issues.
Linked to these broad clinical and research objectives is a
need to disseminate principles of geriatric cardiology to CV
caregivers and patients so that they are better equipped to
work together in developing a care plan most suited to the
patient’s needs and expectations. Despite an increasingly
robust literature focused on geriatric cardiology, it is re-
markable that aging has yet to become a top educational
priority for CV providers. Ironically, there is no longer a
mainstream geriatric cardiology journal in the UnitedStates, in part because publishers are skeptical that such a
journal can be published profitably; yet, it is critical that
geriatric perspectives be infused into management of all
forms of CVD prevalent in older adults.
Conclusions
Mainstream cardiology has become, de facto, geriatric
cardiology, but it still lacks a systematic approach that
incorporates age-related complexities into routine clinical
decision making. The cardiology community must grow and
adapt standards of evidence-based care to older patients,
who now constitute the dominant patient population. Car-
diology must embrace a broader paradigm that extends
beyond the CV system, synthesizing multisystem aging,
comorbidities, polypharmacy, psychosocial factors, and per-
sonal preferences into an individualized approach to care.
Transitioning to this new paradigm is essential to ensure
provision of optimal care for our older patients with CVD,
both for clinical outcomes and patient satisfaction. A new
generation of clinical trials and high-quality observational
studies and registries are essential if we are to refine
standards and methods for requisite care. New approaches
and skills geared toward the elderly must be refined and
inculcated into routine care if cardiologists are to preserve a
benchmark of excellence and clinical relevance.
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